

List of EBE Member Companies

(as of March 2008)

Abbott	LFB Biotechnologies
Actelion	Maxygen
Alexion Europe	MediGene
Amgen	Neurochem
Ardana Bioscience	Newron
Ark Therapeutics	Nexatio
Austrianova	Novartis
Barrier Therapeutics	Novo Nordisk
Basilea	Novozymes
Baxter	Opi
Bayer	Orphan Europe
Bioalliance Pharma	OSI Pharmaceuticals
Biogen Idec	Paion
Boehringer Ingelheim	Pharma Mar
Celgene	Pharmion
Cellerix	Pfizer
Centocor	PregLem
Cephalon Europe	ProtAffin
Chiesi Farmaceutici	PTC Therapeutics
Diatos	Rheoscience
Eli Lilly	Roche
Fibrex Medical	Santaris Pharma
Fresenius Biotech	Schering-Plough
Genesis Pharma	Shire
Genethon	Speedel
Genmab	Swedish Orphan
Genzyme	Symphogen
HGS Europe	Syntaxin
HRA Pharma	Tibotec
Hybrigenics	TcLand
Intercell	UCB
Ipsen	Wyeth
Jerini	Zymenex

www.ebe-biopharma.org

European Biopharmaceutical Enterprises (EBE),
a specialised group of EFPIA

Rue du Trône 108 Tel: + 32 2 626 2561
BE – 1050 Brussels Fax: + 32 2 626 2566
Belgium info@ebe-biopharma.org

design by karakas.be

european biopharmaceutical enterprises

The Voice of Biopharmaceuticals in Europe

ebe



EBE supports the business of its members and helps raise the competitiveness of the biopharmaceutical sector in Europe, with a view towards profitability, economic growth, and ultimately to saving lives.

The Voice of Biopharmaceuticals in Europe

The mission of “European Biopharmaceutical Enterprises” (EBE) is to:

- Represent biopharmaceutical companies of all sizes operating in Europe in the formulation of policies at global and European levels.
- Support innovation initiatives and new opportunities for biopharmaceutical technologies in the European knowledge-based economy.
- Contribute industry expertise to the development of new regulatory frameworks, guidelines and standards of relevance to biopharmaceuticals.
- Promote the exchange of good practices to foster the development of safe, efficacious and high-quality medicines.
- Increase awareness of the sector, its products and the tangible benefits that biopharmaceuticals bring to patients and society worldwide.
- Support the business development of member companies, especially SMEs, through advice, networking, training and educational opportunities.
- Facilitate information exchange and communications between all stakeholders in the biopharmaceuticals field through EBE acting as resource centre.

Become a Member of EBE

European Biopharmaceutical Enterprises (EBE) is the European trade association that represents biopharmaceutical companies of all sizes operating in Europe. It was established in 2000 as a specialised group of EFPIA and is headquartered in Brussels. Membership in EBE is open to all companies using biotechnology to discover, develop and bring new medicinal products to market.

EBE's focus on the biopharmaceutical sector provides targeted and results-oriented support for its members. It has developed a wide range of activities and services for members, embracing policy advocacy, regulatory intelligence, strategic communications, business development, networking, education and training.

EBE coordinates specialised committees and task forces composed of member company representatives to provide industry input to the European legislative and regulatory process. EBE has also developed specific programmes to address technical matters (e.g. biotech manufacturing) and cover growing niche markets (e.g. orphan medicinal products).

If your company is not an EBE member yet, you should request a membership pack from the EBE office and evaluate our membership value proposition!



Biotechnology Brings New Solutions to Healthcare

All stakeholders should stand to benefit from the advances in healthcare that biopharmaceutical technology offers and they all have a role to play. EBE has become a key focal point for information exchange between the research-based biopharmaceutical industry operating in Europe and all major stakeholders engaged in this process.

For example, through EBE, policy makers can meet with the sector to understand the business implications of existing or proposed legislation regulating biopharmaceutical product development and distribution. The number and complexity of regulations affecting the biopharmaceutical sector is also increasing and regulators need a forum for industry consultation.

